COPENHAGEN |
Tue Dec 25, 2012 5:49am EST
COPENHAGEN (Reuters) – Danish drugmaker Novo Nordisk pronounced on Tuesday Japan’s health regulator had authorized a new multiple insulin, that it skeleton to marketplace as Ryzodeg, for a diagnosis of diabetes.
Ryzodeg is a multiple of Novo’s new ultra long-acting insulin degludec, or Tresiba, that Japan became a initial nation to approve in September, and a rapid-acting insulin Novorapid.
Tresiba, Novo’s biggest new drug hope, had a reversal in Nov when regulators in a United States, where Novo expects to beget a bulk of sales, pronounced Tresiba has a aloft heart reserve risk than other diabetes treatments, lifting fears that it might not be authorized there.
Novo has also filed for capitulation of a drug in a European Union, Canada, Switzerland and other countries.
Tresiba and Ryzodeg are seen as clever new competitors in a long-acting, or basal, insulin market, that has prolonged been dominated by Sanofi’s Lantus. Competition is hotting adult in a space, with Eli Lilly also carrying a earnest new contender in development.
Novo has pronounced formerly that a accurate timing for a launch of Ryzodeg would be motionless after a cost inventory for Tresiba, that it skeleton to launch in Japan shortly after execution of cost talks.
(Reporting around Stockholm newsroom; modifying by Patrick Graham)
Source: Health Medicine Network